GOSSAMER BIO, INC. Cash and Restricted Cash
GOSSAMER BIO, INC. (GOSS) had Cash and Restricted Cash of $41.15 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.15M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.03M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $37.73M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.93M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $41.15M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $41.03M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $37.73M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $8.93M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $26.31M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $29.02M 10-Q · filed 2026-05-15 | |
| 2024-12-31 | $46.07M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $28.46M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $86.88M 10-Q · filed 2025-08-05 | |
| 2024-03-31 | $38.86M 10-Q · filed 2025-05-15 | |
| 2023-12-31 | $32.11M 10-K · filed 2026-03-17 | |
| 2023-09-30 | $82.61M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $37.00M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $65.24M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $111.97M 10-K · filed 2026-03-17 | |
| 2022-09-30 | $153.48M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $94.32M 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $138.97M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $183.47M 10-K · filed 2025-03-13 | |
| 2021-09-30 | $213.54M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $343.02M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $439.98M 10-Q · filed 2022-05-10 | $440.22M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $486.62M 10-K · filed 2024-03-05 | |
| 2020-09-30 | $461.96M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $486.06M 10-Q · filed 2021-08-09 | |
| 2020-03-31 | $111.35M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $135.09M 10-K · filed 2023-03-17 | |
| 2019-09-30 | $130.71M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $148.50M 10-Q · filed 2020-08-11 | |
| 2019-03-31 | $170.85M 10-Q · filed 2020-05-12 | |
| 2018-12-31 | $105.42M 10-K · filed 2022-03-03 | |
| 2018-09-30 | $141.27M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $32.35M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $79.18M 10-Q · filed 2019-05-14 | |
| 2017-12-31 | $315.00K 10-K · filed 2021-02-26 | |
| 2016-12-31 | $60.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |